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Wilhelminenspital Vienna, Vienna, AustriaIntroduction. The purpose of this cohort study was to evaluate the effect of carotid endarterectomy under local anaesthesia
on homocysteine (Hcy) concentrations.
Patients and methods. Of 100 patients with internal carotid artery (ICA) stenosis O70%, the complete data set was
available for 91 patients (39 asymptomatic and 52 symptomatic). All patients underwent eversion endarterectomy of the
ICA under regional anaesthesia.
Results. Thirty-two percent of the examined patients had a total Hcy above 15 mmol/l. The mean Hcy levels preoperatively
were 13.9G4.8 mmol/l. The Hcy levels on day 5 were 13.1G5.0 mmol/l and after 6 months 14.0G5.8 mmol/l. There was no
significant change during follow-up. No intraoperative strokes and deaths were observed and during the 6 months follow-up
no recurrent strokes, TIAs or deaths occurred.
Conclusion. Patients undergoing carotid endarterectomy under regional anaesthesia do not have an increase in total Hcy
postoperatively. This finding is in contrast to results from cardiac surgery and carotid endarterectomy in a recently
published animal study, both performing surgery under general anaesthesia.Keywords: Homocysteine; Carotid endarterectomy; Regional anaesthesia; Risk factor.Introduction
Homocysteine (Hcy) is a sulphur-containing amino
acid formed during methionine metabolism.1 Elevated
plasma homocysteine levels are a recognised indepen-
dent risk factor for coronary, cerebral, and peripheral
arterial occlusive disease.2–4 Literature regarding the
effect of operative procedures on plasma homocys-
teine levels are sparse. There is growing evidence that
homocysteine may play a role in postprocedural
intimal hyperplasia and arterial thrombosis and,
therefore, the effect of surgery on homocysteine levels
is important.
In humans, it was reported that coronary bypass
grafting leads to sustained elevation of homocysteine
levels.5 In a recently published animal study, it was
shown that carotid endarterectomy under general
anaesthesia leads to sustained and marked elevation
of homocysteine.6 This study suggested thating author. Dr Afshin Assadian, MD, Department of
Vascular Surgery, Wilhelminenspital Vienna, Vienna,
: afshin_assadian@yahoo.de
0617 + 04 $35.00/0 q 2005 Elsevier Ltd. All rights reseranaesthetics alone, surgical dissection, and manipu-
lation of the intima within the artery were not the
prime aetiological factors in producing elevated
homocysteine levels. The authors concluded that the
carotid artery itself needs to be clamped and an
endarterectomy performed to produce a significant
six-fold increase in plasma homocysteine.6
The purpose of this cohort study was to evaluate the
effect of carotid endarterectomy under local anaes-
thesia on plasma homocysteine levels in patients
undergoing elective carotid endarterectomy.Patients and MethodsPatient recruitment
One hundred consecutive patients with symptomatic
and asymptomatic internal carotid artery (ICA)
stenosis O70% who were admitted to our department
for surgery were enrolled in the study. All patients
were planned for routine eversion endarterectomyEur J Vasc Endovasc Surg 30, 617–620 (2005)
doi:10.1016/j.ejvs.2005.05.042, available online at http://www.sciencedirect.com onved.
A. Assadian et al.618(EEA) of the ICA under regional anaesthesia. As an
anaesthetic agent, 1% lidocaine was routinely used
for a combined superficial and deep cervical block.
All patients underwent preoperatively duplex
scanning and magnetic resonance angiography to
assess the maximum lumen reduction of the ICA.
Symptomatic patients with stroke had an interval
of less than 6 weeks prior to surgery; symptomatic
patients with transient hemispheric and non-
hemispheric symptoms were all operated on within
3 weeks of presentation. Patients were counselled
and encouraged to reduce cardiovascular risk-
factors and to eat a healthy diet. Patients on
vitamin supplementation were excluded from the
study. All patients had a preoperative measure-
ment of fasting total serum homocysteine 1 day
prior to surgery. The second blood sample for
fasting homocysteine testing was drawn on day 5
after surgery; the final sample was obtained 6
months after surgery. All patients gave written
informed consent. The study was approved by the
local ethics committee.Patients
The demographic data of patients are listed in Table 1.
All three-blood samples were available for 91 patients.
Of the 91 patients included in the evaluation, 53 were
male and 38 were female. The age ranged from 41 to 86
years (medianZ69; Q25thZ62; Q75thZ77). Thirty-
nine patients (43%) had asymptomatic ICA stenosis, 32
patients (35%) had transient ischaemic episodes and
20 patients (22%) were operated on for non-disabling
stroke.Sample handling and homocysteine measurement
Blood was drawn by venipuncture of the ante-
cubital vein and collected in standard K3-EDTA
tubes (Vacuette EDTA Tubes, Greiner Bio-One,Table 1. Patients’ basic demographic data
Male (nZ53) Female
Age 41–83; 70 (62; 76) 47–86;
BMI 27.1G4.1 26.1G3
Alcohol g/week 0–805; 25 (0;120) 0–405;
Nicotine (cigarettes/day) 0–80; 0 (0;10) 0–25; 0
Hypertension 41 (77%) 32 (84%
Diabetes 21 (39%) 4 (10%
ICA stenosis, asymptomatic 20 (38%) 19 (50%
ICA stenosis, TIA 19 (36%) 13 (34%
ICA stenosis, stroke 14 (27%) 6 (16%
Basic demographic data. BMI, body mass index; TIA, transient ischaem
considered significant.
Eur J Vasc Endovasc Surg Vol 30, 12 2005Kremsmu¨nster, Austria). Blood samples were cen-
trifuged (10 min at 2000 g) and plasma was
decanted within 15 min after sampling. Plasma
samples were stored at K80 8C until analysis.
Homocysteine measurements were performed on
an Abbott AxSYM Plus Immunology analyzer
(Abbott Diagnostics, Abbott Park, IL, USA) using
Abbott AxSYM Hcy reagents according to manu-
facturer ’s instructions. The sensitivity of the
AxSYM homocysteine assay was assessed to be
0.8 mmol/l by replicate analyses of the zero-level
calibrator. Sensitivity was defined as the concen-
tration at two standard deviations from the mean
and represents the lowest measurable concentration
of homocysteine that can be distinguished from
zero. The coefficient of variation (CV) resulting
from intra-assay precision experiments was
between 4.5 and 1.4% at concentrations ranging
from 7.6 to 28.2 mmol/l. Evaluating inter-assay
imprecision in the same concentration range the
CV was between 2.0 and 5.1%.Statistics
The results were analysed using a software package
(Epi-Info 2002 software package, Centers for Disease
Control and Prevention, GA, Atlanta). Continuous
variables were analysed to evaluate normality of
distribution. When data were normally distributed
they were presented as meanGSD; means were
compared with a Student’s t-test for unpaired
variables. When distribution was non-normal, vari-
ables were expressed as median and percentile range
(Q25th; Q75th) and compared with the Wilcoxon rank
sum test. Discrete variables were expressed as
numbers (percentages) and compared by chi-square
test or by Fisher’s exact test. To calculate linear
correlation for comparing three unmatched groups,
the Kruskal-Wallis test was performed. All tests of(nZ38) Total (nZ91) P-value
68 (59; 79) 41–86; 69 (62; 77) 0.912
.7 26.7G3.9 0.252
0 (0;0) 0–805; 0 (0;50) 0.006*
(0;10) 0–80; 0 (0;10) 0.369
) 73 (80%) 0.418
) 25 (27%) 0.002*
) 39 (43%) 0.244
) 32 (35%) 0.872
) 20 (22%) 0.227
ic attack; *, statistically significant results; p-values of ! 0.05 were
Effect of CEA on HCY 619significance were two-tailed; P values of %.05 were
considered significant.Fig. 1. Changes of homocysteine levels. Hcy 1, preoperative
homocysteine levels; Hcy 2, postoperative homocysteine
levels day 5; Hcy 3, postoperative homocysteine levels 6
months postoperatively. Blue bars representing asympto-
matic patients; red bars representing patients with transient
ischaemic attacks; yellow bars representing patients with
non-disabling stroke.Results
All three homocysteine samples were obtained in 91
patients. Two patients decided to have general anaes-
thesia and were not followed up. Three patients refused
to have their blood drawn at the scheduled first
postoperative assessment and four patients refused to
have the third blood sampling. One patient had an
intraoperative TIA without CT changes and had no
residual symptoms after 1 h. No intraoperative strokes
and deaths were observed and during the 6 month
follow-upnorecurrentstrokes,TIAsordeathswereseen.
Thirty-two percent of the examined patients had a
total Hcy above 15 mmol/l. Comparisons of total Hcy
levels above and below 15 mmol/l are listed in Table 2.
The mean Hcy levels preoperatively were 13.9G
4.8 mmol/l. The Hcy levels on day 5 were 13.1G
5.0 mmol/l, and after 6 months 14.0G5.8 mmol/l
(Fig. 1). There was no statistically significant elevation
during follow-up (PZ0.370). This applied equally to
homocysteine levels thought to be normal as well as to
patients with homocysteine level elevations above 10.5
and 15 mmol/l. Also, there was no increase in
homocysteine levels in the subgroups of asympto-
matic patients, patients with transient ischaemic
events or patients with non-disabling stroke.Discussion
Mechanisms by which homocysteine may cause
vascular disease are increased production of hydrogen
peroxide,7 increased oxidation of low-density lipopro-
tein8 and endothelial dysfunction.9,10 Additionally,
impaired thrombolysis11 may lead to hypercoagul-
ability. Homocysteine does alter the normalTable 2. Comparison of total homocysteine levels above and below 1
Hcy!15 (nZ62)
Age 41–86; 65 (60; 72)
Sex MZ32; FZ30
BMI 26.8G4.1 (18.0–39.0)
Alcohol g/week 0–805; 0 (0;39.5)
Nicotine (cigarettes/day) 0–40; 0 (0;10)
Hypertension NoZ10; yesZ52
Diabetes NoZ46; yesZ16
ICA stenosis, asymptomatic 23 (37%)
ICA stenosis, TIA 25 (40%)
ICA stenosis, stroke 14 (23%)
Risk factors and demographic data of patients with total Hcy above an
attack; *, statistically significant results; p-values of ! 0.05 were considantithrombotic phenotype of the endothelium by
enhancing the activities of factor XII12 and factor V13
and depressing the activation of protein C.14 It also
inhibits the expression of thrombomodulin,15 induces
the expression of tissue factor16 and suppresses the
expression of endothelial heparan sulphate.17 All of these
effects ultimately facilitate the formation of thrombin and
create a prothrombotic environment. Homocysteine is
also a potent mitogen for vascular smooth-muscle cells.
In vitro, exposure to homocysteine leads to a marked
increase in vascular smooth-muscle cell proliferation18
and it has been proposed that homocysteine promotes
atherogenesis specifically by inducing the proliferation
of vascular smooth-muscle cells.19
These effects may be of clinical importance after
vascular surgery as hypercoagulability can increase
the incidence of thromboembolic ischaemic events and
vascular smooth-muscle cell proliferation can ulti-
mately lead to neo-intimal hyperplasia and hence,
early restenosis.
In our patient population, we could not observe any
rise in postoperative homocysteine levels. Previous5 mmol/l
HcyO15 (nZ29) P-value
47–85; 76 (69; 80) 0.006*
MZ21; FZ8 0.061
26.6G3.6 (20.0–34.8) 0.919
0–455: 0 (0;120) 0.255
0–80; 0 (0;10) 0.380
NoZ8; yesZ21 0.201
NoZ20; yesZ9 0.602
16 (55%) 0.011*
7 (24%) 0.015*
6 (21%) 0.733
d below 15 mmol/l. BMI, body mass index; TIA, transient ischaemic
ered significant.
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patients or animals operated on under general
anaesthesia. As all patients included in this study
were operated on under regional anaesthesia, general
anaesthesia may be a mechanism for inducing
sustained postoperative homocysteine elevations
after carotid endarterectomy. Whether ICA revascular-
isation under general anaesthesia does cause increased
postoperative homocysteine levels in humans may
deserve evaluation as it could be an explanation for
lower cardiac and cerebral morbidity of local versus
general anaesthesia in carotid surgery.20
Serum homocysteine concentrations varied
depending on presenting symptom. Of the asympto-
matic patients with ICA stenosis, 55% had a total
homocysteine above 15 mmol/l. Of the symptomatic
patients, 24% with a transient neurological deficit and
21% with a non-disabling stroke had a total homo-
cysteine above 15 mmol/l. This finding is not in
keeping with the hypothesis that a procoagulative
state due to elevated homocysteine may lead to stroke.
However, our patient numbers may not be adequate to
allow a generalisation regarding the prevalence of
elevated homocysteine for different clinical stages of
haemodynamically relevant ICA stenosis.
In summary, patients undergoing carotid endarter-
ectomy under regional anaesthesia do not have an
increase in total homocysteine postoperatively. This
finding is in contrast to results from cardiac surgery
and carotid endarterectomy in a recently published
animal study, both performing surgery under general
anaesthesia.Acknowledgements
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